secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-273808
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara's Phase 2 ATA188 for non-active PMS misses primary endpoint; cash runway extended beyond Q3 2025
--------------------------------------------------------------------------------

- EMBOLD misses primary endpoint; treatment arm CDI 6% vs 33% in Phase 1; placebo rate 16% exceeded expected 4-6%.
- No new safety signals observed; favorable safety profile for ATA188 in the study.
- Company plans significant expense reductions on ATA188; focuses on allogeneic CAR-T pipeline; cash runway extended beyond Q3 2025.
- Catalysts: ATA3431 preclinical data at ASH Dec 2023; Phase 1 data for ATA3219 in B-NHL expected H2 2024.
- Tab-cel partnership with Pierre Fabre provides additional payments and significant double-digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523273808/0001193125-23-273808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523273808/d139069d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-273808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer